Early GSK price reductions
February 1, 2012
GLAXOSMITHKLINE is reducing
the price of its F2 medicines
impacted by the price disclosure
reduction one month earlier than
required, on 01 March 2012.
The mandatory price disclosure
for all medicines listed on the F2
formulary is part of the
Memorandum of Understanding
between Medicines Australia and
the Government, the result of
which includes the application of a
price disclosure reduction to a
number of PBS listed medicines
from 01 April 2012.
GSK medicines affected by this,
and which will be discounted from
01 March, include Amoxil
(amoxycillin), Aropax (paroxetine),
Augmentin (amoxycillin and
clavulanic acid), Avandamet
(rosiglitazone & metformin) and
Lamictal (lamotrigine).
GSK has said that the early
reduction is designed to minimise
the risk of interruption to patient
access to medicines, and to assist
pharmacists with stock
management.
“We are committed to increasing
access to our medicines and
vaccines,” said David Herd, Director
Healthcare Environment.
“By striving to meet society’s
healthcare needs, we build trust in
our business,” he added.
The above article was sent to subscribers in Pharmacy Daily's issue from 01 Feb 12To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 01 Feb 12
